NCT06466265View on ClinicalTrials.gov

Study of DNP002 in Patients With Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

May 24, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

June 30, 2025

Conditions
Advanced Solid Tumor
Interventions
DRUG

DNP002

Anti-CEACAM6 monoclonal antibody

Trial Locations (1)

10408

RECRUITING

National Cancer Center, Goyang-si

All Listed Sponsors
lead

Kumho HT Inc.

INDUSTRY

NCT06466265 - Study of DNP002 in Patients With Solid Tumors | Biotech Hunter | Biotech Hunter